8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Dec 8, 2025·SEC
Arcutis Biotherapeutics, Inc.(ARQT)Earnings, Financials & Key Ratios
ARQT•NASDAQ
Price updated Jun 19, 2026
AboutArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Show more
- Revenue$376M+91.3%
- EBITDA-$7M+94.5%
- Net Income-$16M+88.5%
- EPS (Diluted)-0.13+88.8%
- Gross Margin90.24%
- EBITDA Margin-1.82%+97.2%
- Operating Margin-3.25%+95.0%
- Net Margin-4.29%+94.0%
- ROE-9.3%+91.8%
ARQT Key Insights
Arcutis Biotherapeutics, Inc. (ARQT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 34.7%
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Expensive at 17.6x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ARQT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARQT Price & Volume
Arcutis Biotherapeutics, Inc. (ARQT) stock price & volume — 10-year historical chart
Loading chart...
ARQT Growth Metrics
Arcutis Biotherapeutics, Inc. (ARQT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years367.27%
TTM95.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM98.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM96.71%
Return on Capital
10 Years-66.24%
5 Years-51.69%
3 Years-39.4%
Last Year-4.28%
ARQT Recent Earnings
Arcutis Biotherapeutics, Inc. (ARQT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.09-350.0%
$0.02
Rev
$105M+1.7%
$104M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.13+333.3%
$0.03
Rev
$130M+14.5%
$113M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.06+160.0%
$0.10
Rev
$99M-10.4%
$111M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.13+27.8%
$0.18
Rev
$82M+1.1%
$81M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.09vs $0.02-350.0% | $105Mvs $104M+1.7% |
| Q1 2026 | Feb 25, 2026 | $0.13vs $0.03+333.3% | $130Mvs $113M+14.5% |
| Q4 2025 | Oct 28, 2025 | $0.06vs $0.10+160.0% | $99Mvs $111M-10.4% |
| Q3 2025 | Aug 6, 2025 | $0.13vs $0.18+27.8% | $82Mvs $81M+1.1% |
Based on last 12 quarters of dataView full earnings history →
ARQT Peer Comparison
Arcutis Biotherapeutics, Inc. (ARQT) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DERM | 171.19M | 6.22 | -13.23 | 10.2% | -14.82% | -35.57% | 0.00 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 HRMY | 1.93B | 33.28 | 12.28 | 21.51% | 16.2% | 17.19% | 0.28 | |
 VNDA | 342.83M | 5.80 | -1.55 | 8.72% | -109.99% | -61.41% | 0.04 |
Compare ARQT vs Peers
Arcutis Biotherapeutics, Inc. (ARQT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARQT Income Statement
Arcutis Biotherapeutics, Inc. (ARQT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 3.69M | 59.61M | 196.54M | 376.07M | 415.62M |
Revenue Growth % | - | - | - | - | - | - | 1517.09% | 229.74% | 91.34% | 95.29% |
Cost of Goods Sold | 0 | 0 | 195K | 455K | 763K | 754K | 4.99M | 19.13M | 36.7M | 37.65M |
COGS % of Revenue | - | - | - | - | - | 20.46% | 8.37% | 9.73% | 9.76% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -195K▲ 0% | -455K▼ 133.3% | -763K▼ 67.7% | 2.93M▲ 484.3% | 54.62M▲ 1762.9% | 177.41M▲ 224.8% | 339.38M▲ 91.3% | 377.98M▲ 0% |
Gross Margin % | - | - | - | - | - | 79.54% | 91.63% | 90.27% | 90.24% | 90.94% |
Gross Profit Growth % | - | - | - | -133.33% | -67.69% | 484.27% | 1762.86% | 224.82% | 91.29% | - |
Operating Expenses | 4.11M | 19.73M | 42.94M | 136.19M | 205.77M | 304.56M | 295.72M | 305.81M | 351.6M | 374.76M |
OpEx % of Revenue | - | - | - | - | - | 8262.59% | 496.12% | 155.6% | 93.49% | - |
Selling, General & Admin | 695K | 1.79M | 6.42M | 20.88M | 60.97M | 122.12M | 185.15M | 229.39M | 274.55M | 284.63M |
SG&A % of Revenue | - | - | - | - | - | 3313.18% | 310.61% | 116.71% | 73.01% | - |
Research & Development | 3.41M | 17.94M | 36.52M | 115.31M | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M | 90.14M |
R&D % of Revenue | - | - | - | - | - | 4949.4% | 185.51% | 38.88% | 20.49% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 173K | 0 | 0 | 0 | 0 | 0 |
Operating Income | -4.11M▲ 0% | -19.73M▼ 380.6% | -43.13M▼ 118.6% | -136.65M▼ 216.8% | -206.53M▼ 51.1% | -301.63M▼ 46.0% | -241.1M▲ 20.1% | -128.4M▲ 46.7% | -12.23M▲ 90.5% | 3.21M▲ 0% |
Operating Margin % | - | - | - | - | - | -8183.04% | -404.49% | -65.33% | -3.25% | 0.77% |
Operating Income Growth % | - | -380.64% | -118.56% | -216.81% | -51.14% | -46.05% | 20.07% | 46.75% | 90.48% | - |
EBITDA | 0 | 0 | -42.94M | -136.19M | -205.77M | -300.37M | -239.22M | -125.8M | -6.86M | 5.6M |
EBITDA Margin % | - | - | - | - | - | -8149.05% | -401.34% | -64.01% | -1.82% | 1.35% |
EBITDA Growth % | - | - | - | -217.19% | -51.09% | -45.98% | 20.36% | 47.41% | 94.55% | 104.83% |
D&A (Non-Cash Add-back) | 4.11M | 19.73M | 195K | 455K | 763K | 1.25M | 1.88M | 2.6M | 5.37M | 2.39M |
EBIT | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -295.81M | -229.31M | -112.22M | -2.89M | 9.82M |
Net Interest Income | 0 | 0 | 1.14M | 967K | 173K | -15.65M | -29.71M | -27.17M | -12.08M | -9.1M |
Interest Income | 0 | 0 | 1.14M | 967K | 173K | 0 | 0 | 0 | 0 | 2.27M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 15.65M | 29.71M | 27.17M | 12.08M | 4.73M |
Other Income/Expense | -872K | 480K | 1.14M | 967K | 173K | -9.83M | -17.93M | -10.99M | -2.74M | -4.6M |
Pretax Income | -4.98M▲ 0% | -19.25M▼ 286.8% | -42M▼ 118.1% | -135.68M▼ 223.1% | -206.36M▼ 52.1% | -311.46M▼ 50.9% | -259.03M▲ 16.8% | -139.39M▲ 46.2% | -14.97M▲ 89.3% | -1.39M▲ 0% |
Pretax Margin % | - | - | - | - | - | -8449.76% | -434.57% | -70.92% | -3.98% | -0.33% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 3.11M | 647K | 1.17M | 985K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -1.2% | -0.46% | -7.82% | -70.81% |
Net Income | -4.98M▲ 0% | -19.25M▼ 286.8% | -42M▼ 118.1% | -135.68M▼ 223.1% | -206.36M▼ 52.1% | -311.46M▼ 50.9% | -262.14M▲ 15.8% | -140.04M▲ 46.6% | -16.14M▲ 88.5% | -2.38M▲ 0% |
Net Margin % | - | - | - | - | - | -8449.76% | -439.79% | -71.25% | -4.29% | -0.57% |
Net Income Growth % | - | -286.8% | -118.1% | -223.07% | -52.09% | -50.93% | 15.83% | 46.58% | 88.47% | 98.17% |
Net Income (Continuing) | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -311.46M | -262.14M | -140.04M | -16.14M | -2.38M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.71▲ 0% | -0.53▲ 88.7% | -1.10▼ 107.5% | -3.80▼ 245.5% | -4.17▼ 9.7% | -5.66▼ 35.7% | -3.78▲ 33.2% | -1.16▲ 69.3% | -0.13▲ 88.8% | -0.02▲ 0% |
EPS Growth % | - | 88.75% | -107.55% | -245.45% | -9.74% | -35.73% | 33.22% | 69.31% | 88.79% | 96.71% |
EPS (Basic) | -4.71 | -0.53 | -1.10 | -3.80 | -4.17 | -5.66 | -3.78 | -1.16 | -0.13 | - |
Diluted Shares Outstanding | 1.06M | 36.24M | 38.09M | 35.67M | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M | 129.37M |
Basic Shares Outstanding | 1.06M | 36.24M | 38.09M | 35.67M | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M | 129.37M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ARQT Balance Sheet
Arcutis Biotherapeutics, Inc. (ARQT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.82M | 51.1M | 106.47M | 292.83M | 402.77M | 437.41M | 330.43M | 335.82M | 411.23M | 438.06M |
Cash & Short-Term Investments | 3.42M | 50.94M | 101.27M | 284.44M | 388.6M | 409.59M | 271.86M | 227.96M | 220.98M | 224M |
Cash Only | 3.42M | 39.39M | 63.34M | 65.08M | 97.99M | 53.64M | 88.4M | 71.33M | 42.91M | 34.76M |
Short-Term Investments | 0 | 11.55M | 37.93M | 219.36M | 290.61M | 355.95M | 183.46M | 156.62M | 178.07M | 189.24M |
Accounts Receivable | 0 | 0 | 0 | 510K | 362K | 8.46M | 25.81M | 73.07M | 146.23M | 144.38M |
Days Sales Outstanding | - | - | - | - | - | 837.54 | 158.03 | 135.69 | 141.92 | 112.5 |
Inventory | 0 | 0 | 0 | 0 | 0 | 7.51M | 13.13M | 14.53M | 22.63M | 37.39M |
Days Inventory Outstanding | - | - | - | - | - | 3.64K | 961.28 | 277.18 | 225.14 | 239.38 |
Other Current Assets | 0 | 0 | 1.89M | 1.54M | 7.66M | 4.46M | 9.53M | 8.82M | 21.39M | 32.29M |
Total Non-Current Assets | 0 | 0 | 538K | 5.44M | 5.38M | 11.87M | 10.93M | 13.07M | 21.74M | 21.95M |
Property, Plant & Equipment | 0 | 0 | 491K | 5.37M | 5.3M | 4.6M | 3.9M | 2.99M | 5.51M | 5.4M |
Fixed Asset Turnover | - | - | - | - | - | 0.80x | 15.28x | 65.65x | 68.25x | 83.90x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 7.19M | 6.44M | 9.48M | 14.81M | 14.25M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 47K | 78K | 78K | 78K | 596K | 596K | 1.42M | 2.3M |
Total Assets | 3.82M▲ 0% | 51.1M▲ 1238.0% | 107.01M▲ 109.4% | 298.27M▲ 178.7% | 408.15M▲ 36.8% | 449.27M▲ 10.1% | 341.37M▼ 24.0% | 348.89M▲ 2.2% | 432.97M▲ 24.1% | 460M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.01x | 0.17x | 0.56x | 0.87x | 1.03x |
Asset Growth % | - | 1237.99% | 109.42% | 178.72% | 36.84% | 10.08% | -24.02% | 2.2% | 24.1% | 21.85% |
Total Current Liabilities | 692K | 2.67M | 5.24M | 22.6M | 33.33M | 37.81M | 46.67M | 81.01M | 129.84M | 163.2M |
Accounts Payable | 537K | 1.8M | 1.41M | 7.14M | 7.35M | 8.83M | 11.99M | 14.22M | 12.53M | 18.3M |
Days Payables Outstanding | - | - | 2.63K | 5.73K | 3.52K | 4.27K | 877.7 | 271.35 | 124.61 | 125.31 |
Short-Term Debt | 0 | 0 | 0 | 0 | 433K | 657K | 0 | 0 | 1M | 7.95M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 116K | 225K | 176K | 16.41M | 13.67M | 19.07M | 20.75M | 116.31M | 136.96M |
Current Ratio | 5.52x | 19.12x | 20.33x | 12.96x | 12.09x | 11.57x | 7.08x | 4.15x | 3.17x | 2.68x |
Quick Ratio | 5.52x | 19.12x | 20.33x | 12.96x | 12.09x | 11.37x | 6.80x | 3.97x | 2.99x | 2.46x |
Cash Conversion Cycle | - | - | - | - | - | 201.94 | 241.61 | 141.53 | 242.45 | 226.58 |
Total Non-Current Liabilities | 8.12M | 72.41M | 313K | 5.05M | 77.15M | 201.89M | 206.03M | 110.33M | 113.66M | 107.15M |
Long-Term Debt | 966K | 0 | 0 | 0 | 72.35M | 197.77M | 201.8M | 107.2M | 5.27M | 5.25M |
Capital Lease Obligations | 0 | 0 | 129K | 4.96M | 4.77M | 4.12M | 3.38M | 2.56M | 0 | 7.39M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7.15M | 72.41M | 184K | 82K | 25K | 0 | 849K | 570K | 108.39M | 101.9M |
Total Liabilities | 8.81M | 75.08M | 5.55M | 27.65M | 110.47M | 239.69M | 252.7M | 191.35M | 243.49M | 270.36M |
Total Debt | 966K | 0 | 307K | 4.96M | 77.56M | 202.54M | 205.92M | 110.58M | 6.27M | 13.2M |
Net Debt | -2.45M | -39.39M | -63.03M | -60.12M | -20.43M | 148.9M | 117.52M | 39.25M | -36.64M | -21.56M |
Debt / Equity | - | - | 0.00x | 0.02x | 0.26x | 0.97x | 2.32x | 0.70x | 0.03x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.36x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -3.85x |
Interest Coverage | - | - | - | - | - | -18.90x | -7.72x | -4.13x | -0.24x | 2.08x |
Total Equity | -4.99M▲ 0% | -23.99M▼ 380.4% | 101.46M▲ 523.0% | 270.62M▲ 166.7% | 297.68M▲ 10.0% | 209.58M▼ 29.6% | 88.67M▼ 57.7% | 157.54M▲ 77.7% | 189.48M▲ 20.3% | 189.65M▲ 0% |
Equity Growth % | - | -380.41% | 522.99% | 166.72% | 10% | -29.59% | -57.69% | 77.68% | 20.27% | 28.67% |
Book Value per Share | -4.73 | -0.66 | 2.66 | 7.59 | 6.03 | 3.81 | 1.28 | 1.30 | 1.49 | 1.47 |
Total Shareholders' Equity | -4.99M | -23.99M | 101.46M | 270.62M | 297.68M | 209.58M | 88.67M | 157.54M | 189.48M | 189.65M |
Common Stock | 0 | 0 | 0 | 4K | 5K | 6K | 9K | 12K | 12K | 12K |
Retained Earnings | -5.02M | -24.28M | -66.27M | -201.95M | -408.31M | -719.76M | -981.9M | -1.12B | -1.14B | -1.15B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -1K | -2K | -255K | -1.09M | 4K | -7K | -44K | -514K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARQT Cash Flow Statement
Arcutis Biotherapeutics, Inc. (ARQT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.77M | -14.09M | -42.84M | -113.03M | -174.63M | -257.71M | -247.06M | -112.16M | -5.63M | 26.99M |
Operating CF Margin % | - | - | - | - | - | -6991.73% | -414.48% | -57.07% | -1.5% | - |
Operating CF Growth % | - | -273.11% | -204.12% | -163.87% | -54.49% | -47.58% | 4.14% | 54.6% | 94.98% | 3903.7% |
Net Income | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -311.46M | -262.14M | -140.04M | -16.14M | -2.38M |
Depreciation & Amortization | 0 | 0 | 68K | 122K | 454K | 934K | 1.52M | 2.6M | 4.67M | 2.1M |
Stock-Based Compensation | 27K | 151K | 824K | 7.94M | 23.89M | 32.68M | 38.81M | 41.73M | 40.36M | 30.59M |
Deferred Taxes | 0 | 0 | 0 | 114K | 3.45M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 897K | 2.91M | -227K | 333K | 309K | 30.3M | -1.75M | -1.37M | 314K | 12.04M |
Working Capital Changes | 279K | 2.11M | -1.5M | 14.13M | 3.62M | -10.18M | -23.5M | -15.08M | -34.83M | -15.35M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -8.46M | -17.35M | -47.26M | -73.16M | -58.96M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -7.51M | -5.62M | -400K | -7.33M | -19.96M |
Change in Payables | 537K | 1.26M | -458K | 5.67M | 245K | 1.56M | 3.15M | 2.23M | -1.69M | 3.61M |
Cash from Investing | 0 | -11.53M | -26.32M | -181.82M | -75.95M | -87.2M | 180.23M | 28.82M | -30.25M | -53.34M |
Capital Expenditures | 0 | 0 | -295K | -321K | -995K | -23.28M | -428K | -143K | -686K | -78K |
CapEx % of Revenue | - | - | - | - | - | 631.66% | 0.72% | 0.07% | 0.18% | 0.02% |
Acquisitions | 0 | 0 | 0 | 181.5M | 74.96M | 22.95M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -11.53M | 0 | -181.5M | -74.96M | -22.95M | 0 | -5M | -10M | -10M |
Cash from Financing | 7.12M | 61.59M | 93.1M | 298.14M | 281.95M | 301.8M | 101.32M | 66.2M | 6.97M | 7.64M |
Debt Issued (Net) | 50K | 0 | 0 | 0 | 73.99M | 125M | 0 | -100M | 0 | 0 |
Equity Issued (Net) | 0 | 61.21M | 94.24M | 297M | 207.49M | 176.05M | 98.9M | 161.68M | 6.97M | 6.17M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 7.07M | 386K | -1.14M | 1.14M | 470K | 751K | 2.42M | 4.52M | 0 | 1.48M |
Net Change in Cash | 3.34M▲ 0% | 35.98M▲ 975.8% | 23.94M▼ 33.5% | 3.29M▼ 86.3% | 31.37M▲ 854.0% | -43.12M▼ 237.5% | 34.45M▲ 179.9% | -17.37M▼ 150.4% | -28.74M▼ 65.4% | -18.65M▲ 0% |
Free Cash Flow | -3.77M▲ 0% | -14.09M▼ 273.1% | -43.13M▼ 206.2% | -113.35M▼ 162.8% | -175.62M▼ 54.9% | -281M▼ 60.0% | -247.49M▲ 11.9% | -112.3M▲ 54.6% | -6.31M▲ 94.4% | 26.92M▲ 0% |
FCF Margin % | - | - | - | - | - | -7623.39% | -415.2% | -57.14% | -1.68% | 6.48% |
FCF Growth % | - | -273.11% | -206.22% | -162.81% | -54.93% | -60% | 11.93% | 54.62% | 94.38% | 123.07% |
FCF per Share | -3.57 | -0.39 | -1.13 | -3.18 | -3.55 | -5.11 | -3.57 | -0.93 | -0.05 | 0.21 |
FCF Conversion (FCF/Net Income) | 0.76x | 0.73x | 1.02x | 0.83x | 0.85x | 0.83x | 0.94x | 0.80x | 0.35x | -11.33x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.62M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARQT Key Ratios
Arcutis Biotherapeutics, Inc. (ARQT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -108.41% | -72.93% | -72.62% | -122.8% | -175.79% | -113.76% | -9.3% | -1.41% |
Return on Invested Capital (ROIC) | - | - | -82.34% | -63.52% | -71.17% | -64.05% | -47.79% | -5.25% | 1.34% |
Gross Margin | - | - | - | - | 79.54% | 91.63% | 90.27% | 90.24% | 90.94% |
Net Margin | - | - | - | - | -8449.76% | -439.79% | -71.25% | -4.29% | -0.57% |
Debt / Equity | - | 0.00x | 0.02x | 0.26x | 0.97x | 2.32x | 0.70x | 0.03x | 0.07x |
Interest Coverage | - | - | - | - | -18.90x | -7.72x | -4.13x | -0.24x | 2.08x |
FCF Conversion | 0.73x | 1.02x | 0.83x | 0.85x | 0.83x | 0.94x | 0.80x | 0.35x | -11.33x |
Revenue Growth | - | - | - | - | - | 1517.09% | 229.74% | 91.34% | 95.29% |
Related:ARQT Dividend History·ARQT Revenue History·ARQT Price History·ARQT P/E History·ARQT Financial Ratios·ARQT Institutional Holders
ARQT SEC Filings & Documents
Arcutis Biotherapeutics, Inc. (ARQT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARQT Frequently Asked Questions
Arcutis Biotherapeutics, Inc. (ARQT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arcutis Biotherapeutics, Inc. (ARQT) reported $415.6M in revenue for fiscal year 2025.
Arcutis Biotherapeutics, Inc. (ARQT) grew revenue by 91.3% over the past year. This is strong growth.
Arcutis Biotherapeutics, Inc. (ARQT) reported a net loss of $2.4M for fiscal year 2025.
Dividend & Returns
Arcutis Biotherapeutics, Inc. (ARQT) has a return on equity (ROE) of -9.3%. Negative ROE indicates the company is unprofitable.
Arcutis Biotherapeutics, Inc. (ARQT) generated $26.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.